Docetaxel and Its Nanoformulations: How Delivery Strategies Could Impact the Therapeutic outcome?

References

• Ema M , HaraH , MatsumotoMet al. Evaluation of developmental neurotoxicity of polysorbate 80 in rats. Reprod. Toxicol.25(1), 89–99 (2008).
   PubMed Web of Science ®Google Scholar
• Mirza A , MithalN. Alcohol intoxication with the new formulation of docetaxel. Clin. Oncol.23(8), 560–561 (2011).
   Web of Science ®Google Scholar
• Sohail MF , RehmanM , SarwarHSet al. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int. J. Nanomed.13, 3145 (2018).
   PubMed Web of Science ®Google Scholar
• Rigon RB , OyafusoMH , FujimuraATet al. Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review. BioMed Res. Int.2015, 841817 (2015).
   PubMed Web of Science ®Google Scholar
• Caster JM , PatelAN , ZhangTet al. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.9(1), e1416 (2017).
   Web of Science ®Google Scholar
• Fu Q , SunJ , ZhangWet al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat. Anticancer Drug Discov.4(3), 262–272 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang L , ZhangN. How nanotechnology can enhance docetaxel therapy. Int. J. Nanomed.8, 2927 (2013).
   PubMed Web of Science ®Google Scholar
• Eloy JO , de SouzaMC , PetrilliRet al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf. B.123, 345–363 (2014).
   PubMed Web of Science ®Google Scholar
• Yadav D , SandeepK , PandeyDet al. Liposomes for drug delivery. J. Biotechnol. Biomater.7, 276 (2017).
   Google Scholar
• Vakili-Ghartavol R , RezayatSM , Faridi-MajidiRet al. Optimization of docetaxel loading conditions in liposomes: proposing potential products for metastatic breast carcinoma chemotherapy. Sci. Rep.10(1), 1–14 (2020).
   PubMed Web of Science ®Google Scholar
• Li N , FuT , FeiWet al. Vitamin ED‐alpha‐tocopheryl polyethylene glycol 1000 succinate‐conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells. J. Pharm. Pharmacol.71(8), 1243–1254 (2019).
   PubMed Web of Science ®Google Scholar
• Deeken JF , SlackR , WeissGJet al. A Phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother. Pharmacol.71(3), 627–633 (2013).
   PubMed Web of Science ®Google Scholar
• Mahalingam D , NemunaitisJJ , MalikLet al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother. Pharmacol.74(6), 1241–1250 (2014).
   PubMed Web of Science ®Google Scholar
• Yadav S , GuptaS. Development and in vitro characterization of docetaxel-loaded ligand appended solid fat nanoemulsions for potential use in breast cancer therapy. Artif. Cells Nanomed. Biotechnol.43(2), 93–102 (2015).
   PubMed Web of Science ®Google Scholar
• Müller RH , MäderK , GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm.50(1), 161–177 (2000).
   PubMed Web of Science ®Google Scholar
• Severino P , AndreaniT , MacedoASet al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug Deliv.750891, 2012 (2012).
   Google Scholar
• da Rocha MCO , da SilvaPB , RadicchiMAet al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J. Nanobiotechnol.18(1), 1–20 (2020).
   PubMed Web of Science ®Google Scholar
• Lee SE , LeeCD , AhnJBet al. Hyaluronic acid-coated solid lipid nanoparticles to overcome drug-resistance in tumor cells. J. Drug Deliv. Sci. Technol.50, 365–371 (2019).
   Web of Science ®Google Scholar
• Mathur P , SharmaS , RawalSet al. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. J. Liposome Res.30(2), 182–196 (2020).
   PubMed Web of Science ®Google Scholar
• Rafiei P , HaddadiA. A robust systematic design: optimization and preparation of polymeric nanoparticles of PLGA for docetaxel intravenous delivery. Mater. Sci. Eng. C.104, 109950 (2019).
   PubMed Web of Science ®Google Scholar
• Jose S , CinuTA , SebastianRet al. Transferrin-conjugated docetaxel–PLGA nanoparticles for tumor targeting: influence on MCF-7 cell cycle. Polymers11(11), 1905 (2019).
   PubMed Web of Science ®Google Scholar
• Chen Z , TaiZ , GuFet al. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur. J. Pharm. Biopharm.107, 130–141 (2016).
   PubMed Web of Science ®Google Scholar
• Ruiz-Gatón L , EspuelasS , LarrañetaEet al. Pegylated poly (anhydride) nanoparticles for oral delivery of docetaxel. Eur. J. Pharm. Biopharm.118, 165–175 (2018).
   Google Scholar
• Sorolla A , WangE , ClemonsTDet al. Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine20, 102003 (2019).
   PubMed Web of Science ®Google Scholar
• Tran PHL , WangT , YangCet al. Development of conjugate-by-conjugate structured nanoparticles for oral delivery of docetaxel. Mater. Sci. Eng. C107, 110346 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang H , LiuX , WuFet al. A novel prostate-specific membrane-antigen (PSMA) targeted micelle-encapsulating wogonin inhibits prostate cancer cell proliferation via inducing intrinsic apoptotic pathway. Int. J. Mol. Sci.17(5), 676 (2016).
   PubMed Web of Science ®Google Scholar
• Houdaihed L , EvansJC , AllenC. Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic. Mol. Pharm.14(8), 2503–2517 (2017).
   PubMedGoogle Scholar
• Atrafi F , van EerdenRA , vanHylckama Vlieg MAet al. Intratumoral comparison of nanoparticle entrapped docetaxel (CPC634) with conventional docetaxel in patients with solid tumors. Clin. Cancer Res.26(14), 3537–3545 (2020).
   PubMed Web of Science ®Google Scholar
• Fu Q , SunJ , ZhangWet al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat. Anticancer Drug Discov.4(3), 262–272 (2009).
   PubMed Web of Science ®Google Scholar
• Date T , NimbalkarV , KamatJet al. Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. J. Control. Rel.271, 60–73 (2018).
   PubMed Web of Science ®Google Scholar
• Dehaini D , FangRH , LukBTet al. Ultra-small lipid–polymer hybrid nanoparticles for tumor-penetrating drug delivery. Nanoscale8(30), 14411–14419 (2016).
   PubMed Web of Science ®Google Scholar
• Liu Y , LiK , PanJet al. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials31(2), 330–338 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang L , ChanJM , GuFet al. Self-assembled lipid− polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano2(8), 1696–1702 (2008).
   PubMed Web of Science ®Google Scholar
• Liu J , ZahediP , ZengFet al. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J. Pharm. Sci.97(8), 3274–3290 (2008).
   PubMed Web of Science ®Google Scholar
• Guo Y , ZhangP , ZhaoQet al. Reduction‐sensitive polymeric micelles based on docetaxel‐polymer conjugates via disulfide linker for efficient cancer therapy. Macromol. Biosci.16(3), 420–431 (2016).
   PubMed Web of Science ®Google Scholar
• Ernsting MJ , TangWL , MacCallumNWet al. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials33(5), 1445–1454 (2012).
   PubMed Web of Science ®Google Scholar
• Markman B , DeSouza PL , DeesECet al. A Phase I study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors. Am. Soc. Clin. Oncol.34(15), 2526 (2016).
   PubMed Web of Science ®Google Scholar
• Singh MK , KunchaM , NayakVLet al. An innovative in situ method of creating hybrid dendrimer nano-assembly: an efficient next generation dendritic platform for drug delivery. Nanomedicine21, 102043 (2019).
   PubMed Web of Science ®Google Scholar
• Du X , YinS , WangYet al. Hyaluronic acid-functionalized half-generation of sectorial dendrimers for anticancer drug delivery and enhanced biocompatibility. Carbohydr. Polym.202, 513–522 (2018).
   PubMed Web of Science ®Google Scholar
• Kannan R , NanceE , KannanSet al. Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications. J. Intern. Med.276(6), 579–617 (2014).
   PubMed Web of Science ®Google Scholar
• Danhier F . To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?J. Control. Rel.244, 108–121 (2016).
   PubMed Web of Science ®Google Scholar